Abiopharma

🔍 Brainard David (Executive)

Company: EverQuote, Inc. (EVER)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 3,172 shares of Class A Common Stock at $7.095 per share (Direct)
  Date: 2026-05-05 | Code: M | equity_swap_involved: false | shares_owned_after: 190,435.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 9,942 shares of Class A Common Stock at $19.42 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: false | shares_owned_after: 180,493.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 3,172 shares of Stock Option (right to buy) at $7.095 per share (Derivative)
  Date: 2026-05-05 | Code: M | Expires: 2033-07-23 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: The option exercises and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025.
• F2: This option was granted on July 24, 2023. The vesting start date for the shares underlying the option is August 20, 2023 and vesting occurs quarterly over a two-year period from the vesting start date.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $19.90, inclusive. The reporting person undertakes to provide EverQuote, Inc., any security holder of EverQuote, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.